Bictegravir-Emtricitabine-Tenofovir

• HIV-1 Infection
• Antiretroviral Therapy
• HIV Treatment
• Single-Tablet HIV Regimen

Bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) is a fixed-dose combination antiretroviral medication used for the treatment of HIV-1 infection. This single-tablet regimen combines an integrase strand transfer inhibitor (INSTI) with two nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) to provide a complete HIV treatment regimen.

Mechanism of Action

This combination contains three antiretroviral agents with distinct mechanisms. Bictegravir inhibits HIV integrase by binding to the integrase active site and blocking the strand transfer step of HIV DNA integration, which is essential for the HIV replication cycle. Emtricitabine is a nucleoside analog of cytidine that is phosphorylated to its active metabolite, emtricitabine triphosphate, which competes with deoxycytidine triphosphate and inhibits HIV reverse transcriptase by terminating the DNA chain. Tenofovir alafenamide is a prodrug of tenofovir that is converted intracellularly to the active metabolite tenofovir diphosphate, which inhibits HIV reverse transcriptase through DNA chain termination.

Available Formulations

The medication is available as fixed-dose combination tablets containing bictegravir 50 mg, emtricitabine 200 mg, and tenofovir alafenamide 25 mg. A lower strength tablet (bictegravir 30 mg/emtricitabine 120 mg/tenofovir alafenamide 15 mg) is available for pediatric patients weighing 14 to less than 25 kg. The tablet can be taken with or without food.

Medical Uses

BIC/FTC/TAF is FDA-approved for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 14 kg who have no antiretroviral treatment history or who are virologically suppressed on a stable antiretroviral regimen with no history of treatment failure and no known resistance to the individual components. Clinical trials demonstrated non-inferiority or superiority compared to other guideline-recommended regimens, with high rates of viral suppression.

Dosing Guidelines

For adults and pediatric patients weighing at least 25 kg, the dose is one tablet (50/200/25 mg) taken orally once daily with or without food. For patients weighing 14 to less than 25 kg, one low-dose tablet (30/120/15 mg) once daily is recommended. If taken with rifabutin, an additional 50 mg dose of bictegravir should be taken with the combination tablet. The medication should not be used with other antiretroviral drugs unless treating hepatitis B coinfection.

Important Safety Information

Severe acute exacerbations of hepatitis B have been reported in patients coinfected with HIV and HBV who discontinued this medication. All patients should be tested for HBV before initiating therapy, and those with HBV coinfection should be monitored closely if therapy is discontinued. Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with nucleoside analogs. Immune reconstitution syndrome may occur during initial HIV treatment. New onset or worsening renal impairment has been observed.

Drug Interactions

Bictegravir is a substrate of CYP3A and UGT1A1. Strong CYP3A inducers (rifampin, St. John's Wort) significantly decrease bictegravir levels and are contraindicated. Dofetilide is contraindicated due to potential increased dofetilide concentrations. Polyvalent cation-containing products (antacids, iron supplements) should be taken at least 2 hours before or after BIC/FTC/TAF. Metformin dose should be limited when taken with this medication. The medication interacts with other antiretrovirals and should not be coadministered unless managing HBV coinfection.

Why a Single-Tablet Regimen Is Usually the Starting Point

Modern HIV treatment is built around driving the viral load to undetectable quickly and keeping it there, and a complete one-pill regimen removes most of the ways that goal is missed. Combining an integrase inhibitor with the two-drug backbone of emtricitabine and tenofovir in a single tablet means a patient cannot accidentally take a partial regimen, which is the situation that breeds resistance; it also means one copay, one refill date, and one thing to carry when traveling. Bictegravir belongs to the second generation of integrase inhibitors, which tolerate an imperfect adherence record better than the first generation did, and this combination is generally well tolerated from the first week.

Before the first tablet a short checklist is worked through. Hepatitis B status is established, because two of the three components also suppress hepatitis B and stopping them abruptly can provoke a severe flare. Kidney function is measured. Pregnancy plans are discussed. Every other medicine is reviewed, including the ones patients do not think of as medicines. And the goal is stated plainly: sustained viral suppression protects the immune system and also means the virus is not transmitted sexually.

What Derails an Otherwise Reliable Regimen

Three problems account for most unexplained rises in viral load. The first is antacids and supplements. Calcium, magnesium, aluminum, iron, and ordinary multivitamins bind the integrase inhibitor in the gut, and a patient who starts a heartburn remedy or an iron tablet without mentioning it can lose much of a dose. The separation rules described above are worth writing on the bottle. The second is a gap in supply — a missed refill, a change of insurance, a hospital admission where the home regimen is not continued — and knowing who to call is more useful than another conversation about adherence. The third is a prescription started elsewhere, particularly rifampin-based tuberculosis treatment or a herbal product containing St. John's wort.

Beyond the virus, care for acquired immune deficiencies is ordinary internal medicine: blood pressure, lipids, weight, bone health, vaccinations, and cancer screening all matter more as people on suppressive therapy live a normal lifespan. Weight gain has been reported with integrase-inhibitor regimens and is tracked rather than assumed. Patients who need a different backbone, or whose resistance history this combination cannot cover, are moved to a regimen built around dolutegravir or a boosted protease inhibitor. The MedlinePlus monograph for bictegravir, emtricitabine, and tenofovir alafenamide and the NIH explanation of HIV treatment basics set this out in patient terms, and our immunology team coordinates the rest of the preventive care.

Special Populations

There are insufficient human data on use during pregnancy. The Antiretroviral Pregnancy Registry monitors outcomes in pregnant women. Emtricitabine and tenofovir are excreted in breast milk; HIV-infected mothers should not breastfeed due to the risk of HIV transmission. Safety and efficacy have been established in pediatric patients weighing at least 14 kg. No dose adjustment is needed for elderly patients. The medication is not recommended for patients with CrCl below 30 mL/min or on dialysis. No dose adjustment is needed for hepatic impairment.